IR-Crizotinib
IR-Crizotinib is a NF-κB-inducing kinase (NIK) inhibitor that crosses the blood-brain barrier and fluorescently localizes intracranial glioblastoma (GBM) in mice (IC50=3.381 μM). IR-Crizotinib is conjugated from the near-infrared dye IR-786 and the NF-κB-inducing kinase (NIK) inhibitor Crizotinib. IR-Crizotinib can effectively inhibit the growth and invasion of glioma in vitro and in vivo and can be used in cancer research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 2387927-74-2
- Fòrmula: C53H57Cl2FIN7O
- Peso molecular:1024.87
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
IC50: NF-κB-inducing kinase (3.381 μM)[1].
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| GBM | EC50 |
15 nM
Compound: 1
|
Synergistic antiproliferative activity against patient-derived GBM cells assessed as cell viability after 48 hrs in presence of temozolomide by 5-Ethynyl-2'-deoxyuridine incorporation assay
Synergistic antiproliferative activity against patient-derived GBM cells assessed as cell viability after 48 hrs in presence of temozolomide by 5-Ethynyl-2'-deoxyuridine incorporation assay
|
[PMID: 31378572] |
| GBM | EC50 |
50 nM
Compound: 1
|
Antiproliferative activity against patient-derived GBM cells assessed as cell viability after 48 hrs by 5-Ethynyl-2'-deoxyuridine incorporation assay
Antiproliferative activity against patient-derived GBM cells assessed as cell viability after 48 hrs by 5-Ethynyl-2'-deoxyuridine incorporation assay
|
[PMID: 31378572] |
| GBM | EC50 |
93.1 nM
Compound: 1
|
Cytotoxicity against patient-derived GBM cells assessed as LDH release after 96 hrs by spectrophotometric method
Cytotoxicity against patient-derived GBM cells assessed as LDH release after 96 hrs by spectrophotometric method
|
[PMID: 31378572] |
| GBM | IC50 |
1 nM
Compound: 1
|
Synergistic antiproliferative activity against patient-derived GBM cells assessed as reduction in cell viability after 48 hrs in presence of temozolomide by 5-Ethynyl-2'-deoxyuridine incorporation assay
Synergistic antiproliferative activity against patient-derived GBM cells assessed as reduction in cell viability after 48 hrs in presence of temozolomide by 5-Ethynyl-2'-deoxyuridine incorporation assay
|
[PMID: 31378572] |
| GBM | IC50 |
4.7 nM
Compound: 1
|
Antiproliferative activity against patient-derived GBM cells assessed as reduction in cell viability after 48 hrs by 5-Ethynyl-2'-deoxyuridine incorporation assay
Antiproliferative activity against patient-derived GBM cells assessed as reduction in cell viability after 48 hrs by 5-Ethynyl-2'-deoxyuridine incorporation assay
|
[PMID: 31378572] |
Chemical Information
-
No. CAS 2387927-74-2
-
Peso molecular 1024.87
-
Fòrmula C53H57Cl2FIN7O
-
SMILES
NC(C(O[C@@H](C1=C(Cl)C=CC(F)=C1Cl)C)=C2)=NC=C2C3=CN(N=C3)C4CCN(C5=C(/C=C/C6=[N+](C)C(C=CC=C7)=C7C6(C)C)CCC/C5=C\C=C8C(C)(C)C(C=CC=C9)=C9N/8C)CC4.[I-]
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
IR-Crizotinib Related Classifications
HY-149696 Related Classifications
Powered by Bioz